Abbvie Inc ABBV

$262.13 +2.20 (0.85%)

Valuation

Market cap
462,175,360,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.22
Forward PE
18.75
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
2,567,646
Avg volume
4,622,682
Day's range
$257.87 – $261.86
Shares out
1,766,793,000
Stochastic %K
9%
Beta
0.29
Analysts
Strong Sell
Price target
$278.20

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

SparkyReturns Oct 2, 2:38 PM
$MRNA Biotech investors, have a breaking investment idea. ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $TAK $ABBV $BAYRY $PFE
0 replies
UltraInstinct Oct 2, 2:13 PM
$ABBV Sleeping giant!!!
0 replies
Hawksssss Oct 2, 3:57 AM
$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.
1 replies
topstockalerts Oct 1, 11:48 PM
ADARx Pharmaceuticals announced that underwriters fully exercised their option to purchase an additional 3,937,500 common shares at $17 per share, with the transaction closing October 1, 2026. The exercise brings total shares sold in the company’s IPO to 30.1875 million, generating approximately $513.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. Separately, AbbVie purchased 5,255,542 ADARx shares at $17 per share through a concurrent private placement. Including the IPO, ADARx raised approximately $602.5 million in total gross proceeds before fees and expenses. The additional capital significantly expands ADARx’s funding base as it advances its pharmaceutical development programs. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank served as lead book-running managers, with LifeSci Capital acting as an additional bookrunner. $ADRX $ABBV
0 replies
Quantumup Oct 1, 6:24 PM
H.C. Wainwright reiterated $SNDX Buy; PT $38 $KURA $ABBV - RHHBY OTSKY BMY INCY AVLN SNY H.C. Wainwright said in its note: Ahead of 3Q earnings, we completed a deeper diligence effort around NPM1m AML biology and market dynamics that provides a granular understanding of the unique headwinds and underappreciated opportunities within R/R NPM1m AML. Our work centered on revisiting commercial assumptions for the NPM1m AML market as compared to KMT2Ar. We spoke to leading hematologist-oncologists to gain a quick perspective on how targeted therapies like Revuforj are being integrated into existing treatment algorithms, and how those protocols diverge between different genetic subsets of AML in both the frontline and R/R setting. Overall, we came away with a nuanced view of the NPM1m market where frequent actionable co-mutations create headwinds from established targeted therapies in treatment sequencing, rather than from menin inhibitors.
0 replies
55X_ROI_Q1_2026 Oct 1, 4:55 PM
$SLS $MRNA • Phase 3 Results are overdue - and Incoming any day now. and while we are seeing Miraculous Survival in this P3 Trial, Aza+ven - BAT for Control Patients has FAILED 5 AML Trials - Including 2 Phase 3 Trials for AML Remission Maintenance $ABBV Verona P3 Failed • VIALE-M FAILED - AML First Remission (CR1) Maintenance - FAILED • VIALE-T FAILED - AML Post Transplant Maintenance Terminated Paradigm FAILED to Increase OS Opti-AML FAILED to Increase OS --- it ain't BAT - it's not complicated - its Gps doing what its done in ALL Prior Trials, Prevent Relapse and extend Survival - Including in 2 Phase 2 trials for AML Remission.
0 replies
DidYouReadThis Oct 1, 4:00 PM
Most likely to #acquire biggest number of #biotechs in 2027? $NVS $ABBV $LLY $JNJ
0 replies
Quantumup Oct 1, 12:33 PM
JPMorgan🏁 $SYRE and said -- We are initiating coverage of Spyre Therapeutics (SYRE) with an Overweight rating and a $110 year-end 2027 price target. PTGX - $JNJ $ABBV LLY PFE BMY MRK ABVX TEVA - SNY TAK SYBX RHHBY Here's what JPMorgan went on to say: https://x.com/Quantumup1/status/2105637128470192546?s=20
0 replies